BELITE BIO, INC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.85 USD | -0.20% |
|
+7.20% | +6.78% |
| May. 14 | Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024 | |
| May. 14 | Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 749.6 | 1,263 | 1,455 | - | - |
| Enterprise Value (EV) 1 | 749.6 | 1,263 | 1,371 | 1,406 | 1,455 |
| P/E ratio | -47.8 x | -38.4 x | -46.6 x | -57.9 x | -76.3 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 146 x | 44.8 x |
| EV / Revenue | - | - | - | 141 x | 44.8 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | -37.1 x | -40.4 x | -53.4 x |
| FCF Yield | - | - | -2.69% | -2.48% | -1.87% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,867 | 27,599 | 29,794 | - | - |
| Reference price 2 | 30.14 | 45.75 | 48.85 | 48.85 | 48.85 |
| Announcement Date | 3/31/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 10 | 32.47 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -12.82 | -31.69 | -31.08 | -32.86 | -23.14 |
| Operating Margin | - | - | - | - | -328.62% | -71.26% |
| Earnings before Tax (EBT) 1 | - | -12.65 | -31.62 | -30.98 | -32.86 | -23.14 |
| Net income 1 | -9.666 | -12.65 | -31.63 | -31.45 | -25.63 | -19.46 |
| Net margin | - | - | - | - | -256.31% | -59.93% |
| EPS 2 | -1.010 | -0.6300 | -1.190 | -1.048 | -0.8440 | -0.6400 |
| Free Cash Flow 1 | - | - | - | -36.91 | -34.8 | -27.25 |
| FCF margin | - | - | - | - | -348.04% | -83.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 3/31/23 | 3/12/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -1.78 | -1.78 | -6.881 | -6.871 | -10.96 | -6.975 | -8.328 | -7.53 | -7.915 | -7.676 | -11.5 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -1.73 | -1.73 | -6.889 | -6.809 | -10.93 | -6.991 | -7.865 | -7.53 | -7.915 | -7.676 | -11.5 |
| Net income 1 | -1.73 | -1.73 | -6.895 | -6.812 | -10.94 | -6.99 | -7.871 | -7.684 | -8.012 | -7.961 | -11.5 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1200 | -0.1200 | -0.3300 | -0.2600 | -0.4000 | -0.2400 | -0.2700 | -0.2560 | -0.2620 | -0.2620 | -0.3300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/11/22 | 8/11/22 | 5/10/23 | 8/9/23 | 11/14/23 | 3/12/24 | 5/14/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 84.9 | 49.8 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -36.9 | -34.8 | -27.3 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.29 | 0.63 | 1.6 |
| Capex / Sales | - | - | - | - | 6.3% | 4.93% |
| Announcement Date | 3/15/22 | 3/31/23 | 3/12/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
48.85
USD
Average target price
56.5
USD
Spread / Average Target
+15.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.78% | 1.46B | |
| +48.64% | 54.63B | |
| -6.44% | 39.92B | |
| +37.07% | 38.82B | |
| +14.28% | 26.86B | |
| -11.17% | 26.22B | |
| -21.40% | 18.78B | |
| +25.64% | 12.21B | |
| +0.96% | 12.16B | |
| +27.04% | 11.94B |
- Stock Market
- Equities
- BLTE Stock
- Financials Belite Bio, Inc
